Sun Pharmaceutical Industries’ drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA).

Generic drugmaker Natco Pharma’s active pharmaceutical igredients (API) manufacturing plant in Mekaguda, Hyderabad, has been issued a Form 483 with one observation by the U.S. Food and Drug ...

Drug major Sun Pharma on Saturday said the US health regulator has issued a Form 483 with 8 observations after inspecting its ...

Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol ...

Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant ...

US FDA issued 8 Form 483 observations to Sun Pharma’s Halol plant following a GMP inspection in December, raise concerns.

Syngene International said that the United States Food and Drug Administration (US FDA) conducted a good clinical practices (GCP) compliance inspection of the company's facility located at Semicon ...

NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 ...

CNBC-TV18 had first reported the US FDA's surprise visit on June 3. The regulator has now issued a Form 483 with eight observations after a GMP inspection at Sun Pharma’s Halol unit.

According to a regulatory filing by the company, the US FDA conducted a Good Manufacturing Practices (GMP) inspection at the ...

Hyderabad: NATCO Pharma Limited has announced that the company has received one observation from the United States Food and Drugs Administration (USFDA) after the inspection at its ...

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...